Alkermes (ALKS) traded higher Monday, May 4, 2026, with the move largely tied to earnings positioning ahead of the company’s scheduled first-quarter 2026 results release and 8:00 a.m. ET conference call on Tuesday, May 5. With the print imminent, incremental buyers often step in to gain exposure to any update on 2026 expectations and early integration progress following the Avadel transaction. (investor.alkermes.com)

Beyond the near-term earnings catalyst, investors have been tracking Alkermes’ sleep-disorders strategy and orexin program. In mid-April, the company highlighted additional Vibrance-1 Phase 2 data for alixorexton in narcolepsy type 1 presented around the American Academy of Neurology 2026 meeting, including sustained improvements through an open-label extension and tolerability commentary—reinforcing interest in the late-stage pipeline ahead of quarterly updates. (investor.alkermes.com)

The key near-term checkpoint is Tuesday morning’s Q1 release and management commentary, including any changes to full-year framing and any early details on commercial execution in sleep medicine. Separately, investors will continue watching corporate governance milestones heading into the May 20, 2026 annual general meeting and previously disclosed leadership transition plans for mid-2026. (investor.alkermes.com)